Kyle Moylan, MD
Hospice and Palliative Medicine · Saint Louis, MONPI 1124052808
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.2% of the total across 34 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 15 manufacturers, the largest accounting for just 13.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $389 and has fallen 96.0% since, to $15 in 2023. Among hospice and palliative medicine clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 34 payments — averaging $15.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$70
- Pfizer$65
- Novo Nordisk$51
- GSK$48
- AbbVie$45
- Lilly USA, LLC$43
- plus $190 from 9 others
What the payments were for
- Food & beverage$48494%
- Education$306%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 4 | $70 |
| Pfizer | 4 | $65 |
| Novo Nordisk | 4 | $51 |
| GSK | 3 | $48 |
| AbbVie(2 entities) | 2 | $45 |
| Lilly USA, LLC | 3 | $43 |
| AstraZeneca | 3 | $37 |
| Johnson & Johnson | 2 | $33 |
| Kowa Pharmaceuticals America, Inc. | 2 | $28 |
| Boehringer Ingelheim | 1 | $18 |
| Sunovion Pharmaceuticals Inc. | 2 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Abbott | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Novartis | 1 | $13 |
How this compares
$514 in reported general payments places this provider in the 90th percentile of 39 hospice and palliative medicine providers in Missouri.
See all hospice and palliative medicine providers in Missouri →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 206 | $192,792 |
| RybelsusSemaglutide | 63 | $67,817 |
| OzempicSemaglutide | 41 | $52,494 |
| JardianceEmpagliflozin | 52 | $51,465 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 90 | $41,703 |
| MounjaroTirzepatide | 19 | $36,851 |
| XareltoRivaroxaban | 26 | $34,899 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 44 | $32,438 |
| Semglee (Yfgn) PenInsulin Glargine-Yfgn | 47 | $23,104 |
| TrulicityDulaglutide | 13 | $22,456 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $19,312 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $16,589 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 55 | $14,016 |
| Atorvastatin Calcium | 835 | $11,226 |
| MyrbetriqMirabegron | 14 | $10,147 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $65 | $202,677240 claims |
| Novo NordiskRybelsus, Ozempic | $51 | $120,311104 claims |
| GSKAnoro Ellipta, Trelegy Ellipta, Arexvy, Breo Ellipta | $48 | $71,373128 claims |
| Lilly USA, LLCMounjaro, Trulicity | $43 | $59,30632 claims |
| Boehringer IngelheimJardiance | $18 | $51,46552 claims |
| Johnson & JohnsonXarelto | $33 | $34,89926 claims |
| Astellas Pharma US IncMyrbetriq | $70 | $10,14714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 39 hospice and palliative medicine providers in Missouri.
Other hospice and palliative medicine in Saint Louis
- Jane LoitmanSaint Louis$486
- Katharine PonzilloSaint Louis$364
- Lindsay SchwalmSaint Louis$140
- Howard EpsteinSaint Louis$129
- Maria DansSaint Louis$122
- Shannon DevlinSaint Louis$117
- Eberechi Nwogu OnyemkpaSaint Louis$88
- Michelle SchultzSaint Louis$68
- Joan RosenbaumSaint Louis$40
- Jonathan MullinSaint Louis$21
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.